Background
HIV-1 envelope glycoprotein (Env) is the primary target for inducing neutralizing antibodies against the virus Env yet only a small fraction of antibodies elicited are directed against conserved epitopes. Thus, the antibodies produced during infection ad vaccination (to date) have been limited in their ability to neutralize heterologous primary isolates. Since interactions between the virus and its receptor and co-receptor are critical for virus entry into the cell, targeting conserved functional epitopes located in or near the receptor and co-receptor binding sites may be the key for developing an effective vaccine. We as well as others have shown that Env-CD4 complexes are capable of inducing broadly neutralizing antibodies, however use of sCD4 as part of the vaccine has the potential for inducing an autoimmune response.
Materials and methods
Therefore, we are evaluating several approaches, including such as CD4 peptide mimetics (CD4M33), small molecules and novel scaffolds such as invasin and tat (onto which the CD4 binding domain is grafted). This may facilitate targeting of conserved functional epitopes on liganded forms of Env and also reduce immune responses directed towards CD4
Results
We have developed and characterized stable Env-CD4M33 complexes and evaluated them in rabbits for inducing neutralizing antibody responses. In a parallel approach, we have used BMS-853 as a filter to identify 100 structurally similar small molecules, and screened them for their ability to compete with CD4 and b12 for binding to Env as well as their ability to induce conformational change as reflected by enhanced binding to 17b binding. We have so far identified three classes of small molecules that: i) compete for CD4 binding only, ii) induce conformational change in Env without competing for CD4, and iii) compete for CD4 binding and induce conformational changes.
Conclusion
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